Filipendula ulmaria

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funder: Universität Wien
3 of 3 findings with company ties

Model organisms1

Outcomes

IL-6

downin human cells1

1 study

Filipendula ulmaria decreases IL-6 in human cells.
“In HMC3 cells, FE significantly downregulated IL-1β, IL-6, and MCP-1 expression at 100 μg/mL without cytotoxicity.”
CellsLPS-stimulatedmicroglia100 μg/mL
Miquelianin and spiraeoside from Filipendula ulmaria mitigate α-synuclein accumulation in C.elegans and reduce the expression of neuroinflammatory cytokines in human microglia
Frontiers in pharmacology11 Feb 2026

Latest

1 in 12 months

Frontiers in Pharmacology27 Feb

Miquelianin and spiraeoside from Filipendula ulmaria mitigate α-synuclein accumulation in C.elegans and reduce the expression of neuroinflammatory cytokines in human microglia

Experiments in wormsInterventions

Paper

Filipendula ulmaria

Outcomes

Latest

Miquelianin and spiraeoside from Filipendula ulmaria mitigate α-synuclein accumulation in C.elegans and reduce the expression of neuroinflammatory cytokines in human microglia

Related